University of Virginia

UVA establishes LaCross Institute for Ethical AI in Business at Darden, funded by largest gift in Darden history, to coordinate and magnify AI research, pedagogy, and engagement across UVA.

Summit Therapeutics' experimental drug ivonescimab reduced lung cancer progression risk by 49% compared to Merck's Keytruda in a Phase 3 trial, with a median progression-free survival of 11 months versus 6 months for Keytruda. Ivonescimab, discovered by Akeso, targets PD-1 and VEGF, showing potential to become a new standard treatment, though further global trials are needed to confirm its superiority over Keytruda plus chemotherapy.

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, has been appointed as chief of Neurosurgical Oncology at Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, and RWJBarnabas Health. Dr. Sherman, an expert in brain and spinal tumors, will also serve as a professor at Rutgers Robert Wood Johnson Medical School and on the medical staff at Robert Wood Johnson University Hospital. He aims to develop a robust research and clinical trials program in New Jersey.